Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium

BACKGROUND: Bipolar disorder (BPD) is a widespread condition characterized by recurring states of mania and depression. Lithium, a direct inhibitor of glycogen synthase kinase 3 (GSK3) activity, and a mainstay in BPD therapeutics, has been proposed to target GSK3 as a mechanism of mood stabilization...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaladchibachi, Sevag A, Doble, Brad, Anthopoulos, Norman, Woodgett, James R, Manoukian, Armen S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1803776/
https://www.ncbi.nlm.nih.gov/pubmed/17295926
http://dx.doi.org/10.1186/1740-3391-5-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1803776/
https://www.ncbi.nlm.nih.gov/pubmed/17295926
http://dx.doi.org/10.1186/1740-3391-5-3

Ejemplares similares